238 related articles for article (PubMed ID: 21434849)
1. Therapy of aggressive pituitary tumors.
Colao A; Grasso LF; Pivonello R; Lombardi G
Expert Opin Pharmacother; 2011 Jul; 12(10):1561-70. PubMed ID: 21434849
[TBL] [Abstract][Full Text] [Related]
2. [Pituitary carcinomas and aggressive adenomas: an overview and new therapeutic options].
Maïza JC; Caron P
Ann Endocrinol (Paris); 2009 Sep; 70 Suppl 1():S12-9. PubMed ID: 19878763
[TBL] [Abstract][Full Text] [Related]
3. Management of aggressive pituitary adenomas: current treatment strategies.
Buchfelder M
Pituitary; 2009; 12(3):256-60. PubMed ID: 19003540
[TBL] [Abstract][Full Text] [Related]
4. Giant prolactinomas: the therapeutic approach.
Moraes AB; Silva CM; Vieira Neto L; Gadelha MR
Clin Endocrinol (Oxf); 2013 Oct; 79(4):447-56. PubMed ID: 23662975
[TBL] [Abstract][Full Text] [Related]
5. Pituitary tumors.
Mehta GU; Jane JA
Curr Opin Neurol; 2012 Dec; 25(6):751-5. PubMed ID: 23108246
[TBL] [Abstract][Full Text] [Related]
6. Multimodality treatment for invasive pituitary adenomas.
Hornyak M; Couldwell WT
Postgrad Med; 2009 Mar; 121(2):168-76. PubMed ID: 19332975
[TBL] [Abstract][Full Text] [Related]
7. [Aggressive and resistant-to-treatment pituitary tumors].
Cuny T; Chanson P
Ann Endocrinol (Paris); 2013 Oct; 74 Suppl 1():S3-12. PubMed ID: 24356289
[TBL] [Abstract][Full Text] [Related]
8. Management of large aggressive nonfunctional pituitary tumors: experimental medical options when surgery and radiation fail.
Miller BA; Rutledge WC; Ioachimescu AG; Oyesiku NM
Neurosurg Clin N Am; 2012 Oct; 23(4):587-94. PubMed ID: 23040745
[TBL] [Abstract][Full Text] [Related]
9. Regulated, adenovirus-mediated delivery of tyrosine hydroxylase suppresses growth of estrogen-induced pituitary prolactinomas.
Williams JC; Stone D; Smith-Arica JR; Morris ID; Lowenstein PR; Castro MG
Mol Ther; 2001 Dec; 4(6):593-602. PubMed ID: 11735344
[TBL] [Abstract][Full Text] [Related]
10. Non-functioning pituitary adenomas.
Chanson P; Brochier S
J Endocrinol Invest; 2005; 28(11 Suppl International):93-9. PubMed ID: 16625856
[TBL] [Abstract][Full Text] [Related]
11. [Indications for surgical treatment of prolactin-secreting pituitary adenomas].
Kalinin PL; Astaf'eva LI; Kadashev BA; Ismailov DB
Zh Vopr Neirokhir Im N N Burdenko; 2017; 81(5):117-124. PubMed ID: 29076475
[TBL] [Abstract][Full Text] [Related]
12. Prolactinomas in children and adolescents.
Colao A; Loche S
Endocr Dev; 2010; 17():146-159. PubMed ID: 19955764
[TBL] [Abstract][Full Text] [Related]
13. Management of resistant prolactinomas.
Olafsdottir A; Schlechte J
Nat Clin Pract Endocrinol Metab; 2006 Oct; 2(10):552-61. PubMed ID: 17024154
[TBL] [Abstract][Full Text] [Related]
14. Confirmation of a new therapeutic option for aggressive or dopamine agonist-resistant prolactin pituitary neuroendocrine tumors.
Raverot G; Vasiljevic A; Jouanneau E; Lasolle H
Eur J Endocrinol; 2019 Aug; 181(2):C1-C3. PubMed ID: 31167164
[TBL] [Abstract][Full Text] [Related]
15. [Pituitary adenomas--where is the treatment heading at the beginning of the 21st century?].
Marek J
Vnitr Lek; 2010 Jul; 56(7):690-4. PubMed ID: 20842914
[TBL] [Abstract][Full Text] [Related]
16. Aggressive prolactinomas: how to manage?
Lasolle H; Ilie MD; Raverot G
Pituitary; 2020 Feb; 23(1):70-77. PubMed ID: 31617128
[TBL] [Abstract][Full Text] [Related]
17. Current management of prolactinomas.
Nomikos P; Buchfelder M; Fahlbusch R
J Neurooncol; 2001 Sep; 54(2):139-50. PubMed ID: 11761431
[TBL] [Abstract][Full Text] [Related]
18. Aggressive Pituitary Adenomas: The Dark Side of the Moon.
Priola SM; Esposito F; Cannavò S; Conti A; Abbritti RV; Barresi V; Baldari S; Ferraù F; Germanò A; Tomasello F; Angileri FF
World Neurosurg; 2017 Jan; 97():140-155. PubMed ID: 27713064
[TBL] [Abstract][Full Text] [Related]
19. Medical versus surgical treatment of prolactinomas: an analysis of treatment outcomes.
Rutkowski MJ; Aghi MK
Expert Rev Endocrinol Metab; 2018 Jan; 13(1):25-33. PubMed ID: 30063440
[TBL] [Abstract][Full Text] [Related]
20. PTTG expression in different experimental and human prolactinomas in relation to dopaminergic control of lactotropes.
Cristina C; Díaz-Torga GS; Goya RG; Kakar SS; Perez-Millán MI; Passos VQ; Giannella-Neto D; Bronstein MD; Becu-Villalobos D
Mol Cancer; 2007 Jan; 6():4. PubMed ID: 17222350
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]